Trial Profile
A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms bTMB-High Basket trial; GOZILA; TMB-H basket
- 20 Jan 2024 Results of substudy from GOZILA , analyzing Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer, presented at the 2024 Gastrointestinal Cancers Symposium
- 20 Jan 2024 Results of exploratory analysis (n=41) assessing safety and efficacy of Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden presented at the 2024 Gastrointestinal Cancers Symposium
- 21 Jun 2022 Status changed from not yet recruiting to active, no longer recruiting.